Analysts expect over 2020 decreasing revenue Amgen

Next Monday the American Amgen will publish its past quarters figures. For this year Amgen's revenue will be around 23,24 billion USD. This is according to the average of the analysts' estimates. This is slightly lower than 2018's revenue of 23,75 billion USD.

Historical revenues and results Amgen plus estimates 2020

stock analysis

The analysts expect for 2020 a net profit of 8,95 billion USD. The majority of the analysts expects for this year a profit per share of 14,67 USD. So the price/earnings-ratio equals 16,02.

For this year the analysts expect a dividend of 5,8 USD per share. Thus the dividend yield equals 2,47 percent. The average dividend yield of the biotech companies equals an attractive 2,29381636379435 percent.

Recent target prices around 251 USD

The most recent recommendations for the biotech company are from Credit Suisse, Oppenheimer & Co and Cowen and Company.

Amgen's market capitalization is around 169,75 billion USD. The Amgen stock was the past 12 months quite unstable. Since last January the stock is even 21 percent higher. This year the stock price moved between 166 and 245 dollar. Since 2008 the stock price is almost 315 percent higher.

Historical stock prices Amgen2007-2020

stock analysis amgen

Click here for dividend . On Monday the stock closed at 235,04 USD.

Analist.nl Nieuwsdienst: +31 084-0032-842
nieuws@analist.nl

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. Analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.